PET Radiochemistry Group, NIBIB, National Institutes of Health, Bethesda, Maryland 20892-1088, USA.
Synapse. 2011 Sep;65(9):910-8. doi: 10.1002/syn.20919. Epub 2011 Apr 11.
Corticotropin-releasing factor (CRF), a neuropeptide, regulates endocrine and autonomic responses to stress through G-protein coupled receptors, CRF(1) or CRF(2) . A PET ligand able to monitor changes in CRF(1) receptor occupancy in vivo would aid in understanding the pathophysiology of stress-related diseases as well as in the clinical development of nonpeptide antagonists with therapeutic value. We have radiolabeled the CRF(1) receptor ligand, [8-(4-bromo-2,6-dimethoxyphenyl)-2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4-yl]-N,N-bis-(2-methoxyethyl)amine (BMK-152) (ClogP = 2.6), at both the 3 and 4 position with [(76) Br]. Using in vitro autoradiography saturation studies the 4-[(76) Br]BMK-152 exhibited high affinity binding to both rat (K(d) = 0.23 ± 0.07 nM; n = 3) and monkey frontal cortex (K(d) = 0.31 ± 0.08 nM; n = 3) consistent with CRF(1) receptor regional distribution whereas with the 3-[(76) Br]BMK-152, the K(d) s could not be determined due to high nonspecific binding. In vitro autoradiography competition studies using [(125) I]Tyr(0) -o-CRF confirmed that 3-Br-BMK-152 (K(i) = 24.4 ± 4.9 nM; n = 3) had lower affinity (70-fold) than 4-Br-BMK-152 (K(i) = 0.35 ± 0.07 nM; n = 3) in monkey frontal cortex and similiar studies using [(125) I]Sauvagine confirmed CRF(1) receptor selectivity. In vivo studies with P-glycoprotein (PGP) knockout mice (KO) and their wild-type littermates (WT) showed that the brain uptake of 3-[(76) Br]BMK/4-[(76) Br]BMK was increased less than twofold in KO versus WT indicating that 3-[(76) Br]BMK-152/4-[(76) Br]BMK was not a Pgp substrate. Rat brain uptakes of 4-[(76) Br] BMK-152 from ex vivo autoradiography studies showed regional localization consistent with known published CRF(1) receptor distribution and potential as a PET ligand for in vivo imaging of CRF(1) receptors.
促肾上腺皮质释放因子(CRF)是一种神经肽,通过 G 蛋白偶联受体(CRF1 或 CRF2)调节内分泌和自主反应。一种能够监测体内 CRF1 受体占有率变化的 PET 配体将有助于了解应激相关疾病的病理生理学,以及具有治疗价值的非肽拮抗剂的临床开发。我们已经在 3 位和 4 位用 [(76)Br] 对 CRF1 受体配体 [8-(4-溴-2,6-二甲氧基苯基)-2,7-二甲基吡唑并[1,5-α][1,3,5]三嗪-4-基]-N,N-双-(2-甲氧基乙基)胺 (BMK-152)(ClogP = 2.6)进行了放射性标记。使用体外放射自显影饱和研究,4-[(76)Br]BMK-152 对大鼠(Kd = 0.23 ± 0.07 nM;n = 3)和猴额皮质(Kd = 0.31 ± 0.08 nM;n = 3)均表现出高亲和力结合,这与 CRF1 受体的区域分布一致,而对于 3-[(76)Br]BMK-152,由于高非特异性结合,无法确定 Kd 值。使用 [(125)I]Tyr(0)-o-CRF 进行的体外放射自显影竞争研究证实,3-Br-BMK-152(Ki = 24.4 ± 4.9 nM;n = 3)在猴额皮质中的亲和力(Ki = 0.35 ± 0.07 nM;n = 3)比 4-Br-BMK-152 低 70 倍(n = 3),类似的研究使用 [(125)I]Sauvagine 证实了 CRF1 受体的选择性。在 P-糖蛋白(PGP)敲除小鼠(KO)及其野生型同窝仔(WT)的体内研究中,与 WT 相比,KO 中 3-[(76)Br]BMK/4-[(76)Br]BMK 的脑摄取增加不到两倍,表明 3-[(76)Br]BMK-152/4-[(76)Br]BMK 不是 Pgp 底物。来自离体放射自显影研究的大鼠脑摄取 4-[(76)Br]BMK-152 显示出与已知的 CRF1 受体分布一致的区域定位,并有可能成为 CRF1 受体体内成像的 PET 配体。